# OnCo record jonathan-strosberg (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/jonathan-strosberg/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "jonathan-strosberg" ;
  schema:name "Jonathan R. Strosberg"@en ;
  schema:description "Led NETTER-1, the trial that made lutetium dotatate the first approved radioligand therapy for neuroendocrine tumours."@en ;
  schema:url <https://onco.cc/people/jonathan-strosberg/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=Strosberg%20J%5BAuthor%5D%20neuroendocrine%20lutetium> ;
  onco:tag "neuroendocrine", "radioligand", "trialist" ;
  schema:jobTitle "Section Head, Neuroendocrine Tumor Program, Moffitt Cancer Center" ;
  onco:cancers <https://onco.cc/cancers/neuroendocrine/> ;
  onco:technologies <https://onco.cc/technologies/radioligand-therapy/> ;
  onco:targets <https://onco.cc/targets/sstr2/> ;
  onco:drugs <https://onco.cc/drugs/lutathera/> ;
  onco:institutions <https://onco.cc/institutions/moffitt/> ;
  onco:trials <https://onco.cc/trials/compete/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-netter-2-lancet-2024/> ;
  schema:affiliation <https://onco.cc/institutions/moffitt/> .